BioSpace News Archive

Drug Development

Electra Therapeutics Presents Late-Breaking Clinical Data at EHA2024 from Ongoing Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced the presentation of clinical data for ELA026 in secondary hemophagocytic lymphohistiocytosis, a life-threatening hyperinflammatory condition.

June 16, 2024
·
5 min read
Drug Development

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial

Positive results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival and showed a favorable trend in overall survival compared to standard-of-care chemoimmunotherapy in previously untreated patients with mantle cell lymphoma.

June 16, 2024
·
18 min read
Drug Development

HUTCHMED Highlights Publication of Phase III ESLIM-01 Results in The Lancet Haematology

HUTCHMED Limited announces that results from ESLIM-01, HUTCHMED’s Phase III trial of sovleplenib, in adult patients with primary immune thrombocytopenia in China, were published in The Lancet Haematology.

June 16, 2024
·
9 min read
Biotech Bay

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

Nurix Therapeutics, Inc. announced the presentation of updated clinical data for NX-5948, an orally bioavailable degrader of Bruton’s tyrosine kinase, being evaluated in an ongoing Phase 1a/b clinical trial in adults with relapsed or refractory B-cell malignancies, including CLL and non-Hodgkin lymphoma.

June 16, 2024
·
9 min read
Pharm Country

Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc. announced that 14-month median follow-up data from the pivotal Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma were shared during an oral presentation at the European Hematology Association Congress 2024 and published in the Journal of Clinical Oncology.

June 16, 2024
·
14 min read
BioMidwest

Berberine Could Treat Eczema-Exacerbated Staphylococcus aureus Infections

Eczema, a skin inflammatory disease that causes dry, itchy and inflamed skin, affects millions worldwide. Eczema is associated with an altered skin microbiome and higher colonization by Staphylococcus aureus.

June 16, 2024
·
2 min read
Biotech Bay

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

Mirum Pharmaceuticals, Inc. announced that it will host an investor call on Monday, June 17 at 8:30 a.m. ET to share interim analysis results from the Volixibat VANTAGE Phase 2b study in primary biliary cholangitis and the Volixibat VISTAS Phase 2b study in primary sclerosing cholangitis.

June 16, 2024
·
2 min read